<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PROPRANOLOL HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(proe-pran'oh-lole)<br/><span class="topboxtradename">Apo-Propranolol <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Detensol <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Inderal, </span><span class="topboxtradename">Inderal LA, </span><span class="topboxtradename">InnoPran XL, </span><span class="topboxtradename">Novopranol <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic antagonist</span>; <span class="classification">antihypertensive agent</span>; <span class="classification">antiarrhythmic, class ii</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg, 40 mg, 60 mg, 80 mg, 90 mg tablets; 60 mg, 80 mg, 120 mg, 160 mg sustained-release capsules; 80 mg, 120 mg delayed-release capsules; 4 mg/mL, 8 mg/mL, 80 mg/mL solution; 1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Nonselective beta-blocker of both cardiac and bronchial adrenoreceptors which competes with epinephrine and norepinephrine
         for available beta-receptor sites. In higher doses, exerts direct quinidine-like effects, which depresses cardiac function
         including contractility and arrhythmias. Lowers both supine and standing blood pressures in hypertensive patients. Mechanism
         of antimigraine action unknown but thought to be related to inhibition of cerebral vasodilation and arteriolar spasms.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Blocks cardiac effects of beta-adrenergic stimulation; as a result, reduces heart rate, myocardial irritability (Class II
         antiarrhythmic) and force of contraction, depresses automaticity of sinus node and ectopic pacemaker, and decreases AV and
         intraventricular conduction velocity. Hypotensive effect is associated with decreased cardiac output, suppressed renin activity,
         as well as beta-blockade. Also decreases platelet aggregability.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Management of cardiac arrhythmias, myocardial infarction, tachyarrhythmias associated with digitalis intoxication, anesthesia,
         and thyrotoxicosis, hypertrophic subaortic stenosis, angina pectoris due to coronary atherosclerosis, pheochromocytoma, hereditary
         essential tremor; also treatment of hypertension alone, but generally with a thiazide or other antihypertensives.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Anxiety states, migraine prophylaxis, essential tremors, schizophrenia, tardive dyskinesia, acute panic symptoms (e.g., stage
         fright), recurrent GI bleeding in cirrhotic patients, treatment of aggression and rage.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Greater than first-degree heart block; CHF, right ventricular failure secondary to pulmonary hypertension; ventricular dysfunction;
         sinus bradycardia, cardiogenic shock, significant aortic or mitral valvular disease; bronchial asthma or bronchospasm, severe
         COPD, pulmonary edema, allergic rhinitis during pollen season; concurrent use with adrenergic-augmenting psychotropic drugs
         or within 2 wk of MAO inhibition therapy; abrupt discontinuation; major depression; peripheral vascular disease, Raynaud's
         disease; pregnancy (category C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Peripheral arterial insufficiency; history of systemic insect sting reaction; patients prone to nonallergenic bronchospasm
         (e.g., chronic bronchitis, emphysema); major surgery; cerebrovascular disease, stroke; renal or hepatic disease; pheochromocytoma,
         vasospastic angina; older adults; diabetes mellitus; patients prone to hypoglycemia; hyperthyroidism, thyrotoxicosis; surgery;
         myasthenia gravis; Wolff-Parkinson-White syndrome; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40 mg b.i.d., usually need 160480 mg/d in divided doses; <b>InnoPran XL</b> dose 80 mg q hs, may increase to 120 mg hs<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 1 mg/kg/d in 2 divided doses (15 mg/kg/d)<br/><span class="rdage">Neonate:</span> <span class="rdroute">PO</span> 0.25 mg/kg q68h (max: 5 mg/kg/d) <span class="rdroute">IV</span> 0.01 mg/kg slow IV push over 10 min q68h prn (max: 0.15 mg/kg q68h)<br/><br/><span class="indicationtitle">Angina</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1020 mg b.i.d. or t.i.d., may need 160320 mg/d in divided doses<br/><br/><span class="indicationtitle">Arrhythmias</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1030 mg t.i.d. or q.i.d. <span class="rdroute">IV</span> 0.53 mg q4h prn<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 14 mg/kg/d in 4 divided doses (max: 16 mg/kg/d) <span class="rdroute">IV</span> 1020 mcg/kg/min over 10 min<br/><br/><span class="indicationtitle">Acute MI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 180240 mg/d in divided doses<br/><br/><span class="indicationtitle">Migraine Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 80 mg/d in divided doses, may need 160240 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Do not give within 2 wk of a MAO inhibitor.</li>
<li>Note that InnoPran XL should be given hs.</li>
<li>Be consistent with regard to giving with food or on an empty stomach to minimize variations in absorption.</li>
<li>Take apical pulse and BP before administering drug. Withhold drug if heart rate 
         </li><li>Ensure that sustained release form is not chewed or crushed. Must be swallowed whole.</li>
<li>Reduce dosage gradually over a period of 12 wk and monitor patient closely when discontinued.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p>
                  				Note: Verify correct IV concentration and rate of infusion for neonates with physician.
                  			
               </p>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted or dilute each 1 mg in 10 mL of D5W.  <span class="methodtype">Intermittent:</span> Dilute a single dose in 50 mL of NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give each 1 mg over 1 min.  <span class="methodtype">Intermittent:</span> Give each dose over 1520 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span>
<b> Amphotericin B cholesteryl complex,</b>
<b>diazoxide.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) in tightly closed, light-resistant containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever; pharyngitis; respiratory distress, weight gain, LE-like reaction, cold extremities, leg fatigue, arthralgia, <span class="speceff-life">anaphylactic/anaphylactoid reactions</span>.  <span class="typehead">Urogenital:</span> Impotence or decreased libido. <span class="typehead">Skin:</span>  Erythematous, psoriasis-like eruptions; pruritus, <span class="speceff-life">Stevens-Johnson syndrome, </span>
<span class="speceff-life">toxic epidermal necrolysis</span>, erythema multiforme, <span class="speceff-life">exfoliative dermatitis</span>, urticaria. Reversible alopecia, hyperkeratoses of scalp, palms, feet; nail changes, dry skin. <span class="typehead">CNS:</span> Drug-induced psychosis, sleep disturbances, depression, <span class="speceff-common">confusion,</span> agitation, giddiness, light-headedness, <span class="speceff-common">fatigue,</span> vertigo, syncope, weakness, <span class="speceff-common">drowsiness,</span> insomnia, vivid dreams, visual hallucinations, delusions, reversible organic brain syndrome. <span class="typehead">CV:</span> Palpitation, profound <span class="speceff-common">bradycardia,</span> AV heart block, cardiac standstill, hypotension, angina pectoris, tachyarrhythmia, acute CHF, peripheral arterial insufficiency
      resembling Raynaud's disease, myotonia, paresthesia of <span class="speceff-common">hands.</span>
<span class="typehead">Special Senses:</span> Dry eyes (gritty sensation), visual disturbances, conjunctivitis, tinnitus, hearing loss, nasal stuffiness. <span class="typehead"> GI:</span> Dry mouth, cheilostomatitis, nausea, vomiting, heartburn, diarrhea, constipation, flatulence, abdominal cramps, mesenteric
      arterial thrombosis, ischemic colitis, pancreatitis. <span class="typehead">Hematologic:</span> Transient eosinophilia, thrombocytopenic or nonthrombocytopenic purpura, <span class="speceff-life">agranulocytosis</span>. <span class="typehead">Metabolic:</span> Hypoglycemia, hyperglycemia, hypocalcemia (patients with hyperthyroidism). <span class="typehead">Respiratory:</span> Dyspnea, <span class="speceff-life">laryngospasm</span>, bronchospasm. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>
<span class="classification">beta-adrenergic blockers</span> may produce false-negative test results in exercise tolerance ECG tests, and elevations in <span class="alt">serum potassium,</span>
<span class="alt">peripheral platelet count,</span>
<span class="alt">serum uric acid,</span>
<span class="alt">serum transaminase,</span>
<span class="alt">alkaline phosphatase,</span>
<span class="alt">lactate dehydrogenase,</span>
<span class="alt">serum creatinine,</span>
<span class="alt">BUN,</span> and an increase or decrease in <span class="alt">blood glucose</span> levels in diabetic patients.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification">phenothiazines</span> have additive hypotensive effects. <span class="classification">beta-adrenergic agonists</span> (e.g., <b>albuterol</b>) antagonize effects. <b>Atropine</b> and <span class="classification">tricyclic antidepressants</span> block bradycardia. <span class="classification">diuretics</span> and other <span class="classification">hypotensive agents</span> increase hypotension. High doses of <b>tubocurarine</b> may potentiate neuromuscular blockade. <b>Cimetidine</b> decreases clearance, increases effects. <span class="classification">antacids</span> may decrease absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Completely absorbed from GI tract but undergoes extensive first-pass metabolism. <span class="typehead">Peak:</span> 6090 min immediate release; 6 h sustained release; 5 min IV. <span class="typehead">Distribution:</span> Widely distributed including CNS, placenta, and breast milk. <span class="typehead"> Metabolism:</span> Almost completely metabolized in liver. <span class="typehead">Elimination:</span> 9095% excreted in urine as metabolites; 14% excreted in feces. <span class="typehead">Half-Life:</span> 2.3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Obtain careful medical history to rule out allergies, asthma, and obstructive pulmonary disease. Propranolol can cause bronchiolar
            constriction even in normal subjects.
         </li>
<li>Monitor apical pulse, respiration, BP, and circulation to extremities closely throughout period of dosage adjustment. Consult
            physician for acceptable parameters.
         </li>
<li>Evaluate adequate control or dosage interval for patients being treated for hypertension by checking blood pressure near end
            of dosage interval or before administration of next dose.
         </li>
<li>Be aware that adverse reactions occur most frequently following IV administration soon after therapy is initiated; however,
            incidence is also high following oral use in the older adult and in patients with impaired kidney function. Reactions may
            or may not be dose related.
         </li>
<li>Lab tests: Obtain periodic hematologic, kidney, liver, and cardiac functions when propranolol is given for prolonged periods.</li>
<li>Monitor I&amp;O ratio and daily weight as significant indexes for detecting fluid retention and developing heart failure.</li>
<li>Consult physician regarding allowable salt intake. Drug plasma volume may increase with consequent risk of CHF if dietary
            sodium is not restricted in patients not receiving concomitant diuretic therapy.
         </li>
<li>Fasting for more than 12 h may induce hypoglycemic effects fostered by propranolol.</li>
<li>If patient complains of cold, painful, or tender feet or hands, examine carefully for evidence of impaired circulation. Peripheral
            pulses may still be present even though circulation is impaired. Caution patient to avoid prolonged exposure of extremities
            to cold.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn usual pulse rate and take radial pulse before each dose. Report to physician if pulse is below the established parameter
            or becomes irregular.
         </li>
<li>Be aware that propranolol suppresses clinical signs of hypoglycemia (e.g., BP changes, increased pulse rate) and may prolong
            hypoglycemia.
         </li>
<li>Understand importance of compliance. Do not alter established regimen (i.e., do not omit, increase, or decrease dosage or
            change dosage interval).
         </li>
<li>Do not discontinue abruptly; can precipitate withdrawal syndrome (e.g., tremulousness, sweating, severe headache, malaise,
            palpitation, rebound hypertension, MI, and life-threatening arrhythmias in patients with angina pectoris).
         </li>
<li>Be aware that drug may cause mild hypotension (experienced as dizziness or lightheadedness) in normotensive patients on prolonged
            therapy. Make position changes slowly and avoid prolonged standing. Notify physician if symptoms persist.
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Consult physician before self-medicating with OTC drugs.</li>
<li>Inform dentist, surgeon, or ophthalmologist that you are taking propranolol (drug lowers normal and elevated intraocular pressure).</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>